Norway - Norwegian - Statens legemiddelverk

glaxosmithkline as - salmeterolxinafoat / flutikasonpropionat - inhalasjonsaerosol, suspensjon - 25 mikrog / 125 mikrog

Norway - Norwegian - Statens legemiddelverk

glaxosmithkline as - salmeterolxinafoat / flutikasonpropionat - inhalasjonsaerosol, suspensjon - 25 mikrog / 250 mikrog

Norway - Norwegian - Statens legemiddelverk

glaxosmithkline as - salmeterolxinafoat / flutikasonpropionat - inhalasjonsaerosol, suspensjon - 25 mikrog / 50 mikrog

Norway - Norwegian - Statens legemiddelverk

glaxosmithkline as - salmeterolxinafoat / flutikasonpropionat - inhalasjonspulver, dosedispensert - 50 mikrog / 500 mikrog

Norway - Norwegian - Statens legemiddelverk

glaxosmithkline as - salmeterolxinafoat / flutikasonpropionat - inhalasjonspulver, dosedispensert - 50 mikrog / 100 mikrog

Norway - Norwegian - Statens legemiddelverk

glaxosmithkline as - salmeterolxinafoat / flutikasonpropionat - inhalasjonspulver, dosedispensert - 50 mikrog / 250 mikrog

Norway - Norwegian - Statens legemiddelverk

mylan ab - salmeterolxinafoat / flutikasonpropionat - inhalasjonsaerosol, suspensjon - 25 mikrog / 250 mikrog

Norway - Norwegian - Statens legemiddelverk

mylan ab - salmeterolxinafoat / flutikasonpropionat - inhalasjonsaerosol, suspensjon - 25 mikrog / 125 mikrog

European Union - Norwegian - EMA (European Medicines Agency)

teva b.v. - salmeterol xinafoate, fluticasone propionate - astma - legemidler for obstruktive sykdommer i luftveiene, - bropair spiromax is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short-acting β₂ agonists.

European Union - Norwegian - EMA (European Medicines Agency)

teva b.v. - salmeterol, fluticasone propionate - pulmonary disease, chronic obstructive; asthma - legemidler for obstruktive sykdommer i luftveiene, - airexar spiromax er indisert for bruk hos voksne i alderen 18 år og eldre. asthmaairexar spiromax is indicated for the regular treatment of patients with severe asthma where use of a combination product (inhaled corticosteroid and long-acting β2 agonist) is appropriate:- patients not adequately controlled on a lower strength corticosteroid combination productor- patients already controlled on a high dose inhaled corticosteroid and long-acting β2 agonist. kronisk obstruktiv lungesykdom (kols)airexar spiromax er indikert for symptomatisk behandling av pasienter med kols, med en fev1.